Clinical trial
A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer
NCT00055419 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00055419 |
|---|---|
| Title | A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer |
| Official title | A Phase II Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms |
| Intervention type | Biological |
| Interventions | Cetuximab |
| Enrollment | 744 |
| Start date | Feb 1, 2003 |
| Primary completion | Jul 1, 2004 |
| Completion | Aug 1, 2004 |
| First posted | Mar 4, 2003 |
| Last update posted | Apr 9, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: